The Dynasty model combines the work of a biotech company with that of a life sciences investor.
The biotech company partners with UK innovators who have developed products that are both relevant to China and already sufficiently developed to be commercialised in China. Dynasty develops the products and shares the downstream value with the innovators. Meanwhile the investment business sources Chinese capital to fund the UK biotech activities, and provides growth capital to larger science businesses in order to develop products in China.
The Dynasty model is a novel alternative to venture capital, powered by foreign direct investment, generating new exports for UK biotechs.
To view English version: click here
To view Chinese version: 点击这里为影片中文字幕
China, Britain and the Dangerous Oaf
Where now for our promising life sciences and medtech relationship with China and the Chinese? The virus crisis seems to have polarised our...Read More
China: so much more than just trade
Caption: Just add friends. Good food will do the rest I am sat with three friends around a table at a local restaurant in Wuhan, China. The...Read More
‘CAMBRIDGE NOTES’: one British family’s love affair with China over 140 years and 6 generations
Ashwell, Herts. 15 November 2019 Dear Friends Re: Publication of Cambridge Notes, promoting friendly exchange between Wuhan and Britai...Read More
UK-China oncology Mission comes to Wuhan
November 2019 is an important date for international science in Wuhan: it was the date when the UK-China Oncology Mission came to town, plac...Read More
Come. To. China.
Sometimes China can seem like a long way away. But for some it is home, life, work environment, normal. The oppo...
"The UK Government recognises the strong potential for collaboration between the UK and China and actively welcomes partnership for innovation.”–UK Government support, Office for Life Sciences 2013
“The UK Life Sciences Strategy recognises that we must use our outstanding science base to its fullest potential in order that we remain at the forefront of the new life sciences landscape. Dynasty itself provides access for international partners to some of the best life science technology in the world.”–UK Government support, Office for Life Sciences 2013
“Dynasty Biotechnology provides further evidence of the UK's position as the global hub for life sciences, attracting global pharma companies to the UK as their European location of choice, and demonstrating the value of UK life sciences innovation in China - one of the world's most important markets. "–UK Government support, Office for Life Sciences 2013
"Dynasty Biotechnology enters the market at a time when all recognise the value of our Sino-UK relationship."–UK Government support, Office for Life Sciences 2013